EML4–ALK alterations are more common in adenocarcinomas and are rarely found in squamous cell histology. In documented cases, the majority of EML4–ALK translocations are identified in squamous cell histology and occur in patients with no or light smoking history. We report an EML4–ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests that EML4–ALK genomic testing may be clinically useful in patients with heavy smoking history.
|Number of pages||4|
|Journal||Cancer Chemotherapy and Pharmacology|
|State||Published - May 1 2018|
Bibliographical notePublisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
- Anti-ALK inhibitor treatment
- EML4–ALK translocation
- Squamous cell lung cancer
ASJC Scopus subject areas
- Cancer Research
- Pharmacology (medical)